However, a different Assessment from Delveinsight indicates that while Epidyolex is about to continue dominating the market and currently being a critical earner for Jazz inside the close to upcoming, a growing amount of feasible alternate treatment plans in the scarce epilepsies, significantly from bexicaserin and zorevunersen, which might be now